160 related articles for article (PubMed ID: 38136322)
1. Inhibition of Survivin Homodimerization Decreases Neuroblastoma Cell Growth.
Dorneburg C; Galiger C; Stadler GL; Westhoff MA; Rasche V; Barth TFE; Debatin KM; Beltinger C
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136322
[TBL] [Abstract][Full Text] [Related]
2. The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells.
Galiger C; Zohora FT; Dorneburg C; Tews D; Debatin KM; Beltinger C
BMC Cancer; 2023 Nov; 23(1):1148. PubMed ID: 38007466
[TBL] [Abstract][Full Text] [Related]
3. A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells.
Peery R; Cui Q; Kyei-Baffour K; Josephraj S; Huang C; Dong Z; Dai M; Zhang JT; Liu JY
Bioorg Med Chem; 2022 Jul; 65():116761. PubMed ID: 35504208
[TBL] [Abstract][Full Text] [Related]
4. BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.
Hagenbuchner J; Kiechl-Kohlendorfer U; Obexer P; Ausserlechner MJ
Oncogene; 2016 Apr; 35(16):2052-61. PubMed ID: 26148234
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Identification of a Novel Lead Targeting Survivin Dimerization for Proteasome-Dependent Degradation.
Peery R; Kyei-Baffour K; Dong Z; Liu J; de Andrade Horn P; Dai M; Liu JY; Zhang JT
J Med Chem; 2020 Jul; 63(13):7243-7251. PubMed ID: 32421328
[TBL] [Abstract][Full Text] [Related]
6. Significance of survivin mRNA expression in prognosis of neuroblastoma.
Ito R; Asami S; Motohashi S; Ootsuka S; Yamaguchi Y; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2005 Apr; 28(4):565-8. PubMed ID: 15802787
[TBL] [Abstract][Full Text] [Related]
7. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma.
Azuhata T; Scott D; Takamizawa S; Wen J; Davidoff A; Fukuzawa M; Sandler A
J Pediatr Surg; 2001 Dec; 36(12):1785-91. PubMed ID: 11733907
[TBL] [Abstract][Full Text] [Related]
8. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
Peirce SK; Findley HW; Prince C; Dasgupta A; Cooper T; Durden DL
Cancer Chemother Pharmacol; 2011 Aug; 68(2):325-35. PubMed ID: 20972874
[TBL] [Abstract][Full Text] [Related]
9. LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.
Dorneburg C; Fischer M; Barth TFE; Mueller-Klieser W; Hero B; Gecht J; Carter DR; de Preter K; Mayer B; Christner L; Speleman F; Marshall GM; Debatin KM; Beltinger C
Clin Cancer Res; 2018 Nov; 24(22):5772-5783. PubMed ID: 29925504
[No Abstract] [Full Text] [Related]
10. Mechanisms of neuroblastoma cell growth inhibition by CARP-1 functional mimetics.
Muthu M; Cheriyan VT; Munie S; Levi E; Frank J; Ashour AE; Singh M; Rishi AK
PLoS One; 2014; 9(7):e102567. PubMed ID: 25033461
[TBL] [Abstract][Full Text] [Related]
11. Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors.
Qi J; Dong Z; Liu J; Peery RC; Zhang S; Liu JY; Zhang JT
Cancer Res; 2016 Jan; 76(2):453-62. PubMed ID: 26744521
[TBL] [Abstract][Full Text] [Related]
12. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.
Obexer P; Hagenbuchner J; Unterkircher T; Sachsenmaier N; Seifarth C; Böck G; Porto V; Geiger K; Ausserlechner M
Mol Biol Cell; 2009 Apr; 20(7):2041-8. PubMed ID: 19211844
[TBL] [Abstract][Full Text] [Related]
13. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
15. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery.
Hagenbuchner J; Kuznetsov AV; Obexer P; Ausserlechner MJ
Oncogene; 2013 Oct; 32(40):4748-57. PubMed ID: 23146905
[TBL] [Abstract][Full Text] [Related]
16. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
Zins K; Kovatchki D; Lucas T; Abraham D
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
[TBL] [Abstract][Full Text] [Related]
17. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
18. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
19. Runt-related transcription factor 1 promotes apoptosis and inhibits neuroblastoma progression in vitro and in vivo.
Hong M; He J; Li D; Chu Y; Pu J; Tong Q; Joshi HC; Tang S; Li S
J Exp Clin Cancer Res; 2020 Mar; 39(1):52. PubMed ID: 32197643
[TBL] [Abstract][Full Text] [Related]
20. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
